Clinical Trial

Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

Study acronym: FOSTAMR
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-06-18; most recent amendment 2024-11-21.
Status change: Recruiting → Active, Not Recruiting 2024-11-21
Trial Details
NCT Number NCT03991780
Lead Sponsor Imperial College London
Conditions Renal Transplant Rejection
Enrollment 8 participants
Start Date 2019-05-08
Primary Completion 2023-04-05 (estimated)
Study Completion 2025-10-15 (estimated)
Updated on ClinicalTrials.gov 2024-11-25